Sheet

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid ONB control number.

Complete if Known

Substituta for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/599,719
Filing Date	October 6, 2006
First Named Inventor	Latin-Yen Hu
Art Unit	
Examiner Name	
Attorney Docket Number	
PC 32225 A	

U. S. PATENT DOCUMENTS Publication Date Name of Patentee or Pages, Columns, Lines, Where Examiner Document Number MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials\* No Number-Kind Code<sup>2 (F known)</sup> Figures Appear HS. US-US-HS. US-US-US-HS. US-US-US. US-US-US-US. HS.

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Dat	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.	
			MM-DD-YYYY		Or Relevant Figures Appear	Te	
		WO9510521A1		Abstract			
		WO9735845A1		Abstract			
		WO99/08673A	02-25-1999	Bristol-Myers Squibb			
		WO99/17777	04-15-1999	Merck & Co. Inc.			
		WO2005000794	01-06-2005	Orion Corp.			
		WO2005013914A	02-17-2005	Vertex Pharm Inc.			

Examiner Date Considered

"EXAMINEE, mind if reference considered, whether or not clation is in conformance with MPEP 609. Date in through clation if not in conformance and not localisated, include copy of this form with next communication to applicate." Applicant's unique clation designation number (optional). See Kinds Codes of USF1O Portion Documents at restrictions or MPEP 901.04. Set for Cliffice that issued the document, by the through claim of the part of the region of the part of the par

This solvenion of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the UPFTO by process) an application. Confidentially is governed by 38 U.S. C.12 and 37 CFR 1-14. This collection is tellimated to be busines to complete upon the public which is to file (and by the UPFTO by process) an application. Confidentially is governed by 38 U.S. C.12 and 37 CFR 1-14. This collection is tellimated by bours to complete, including pathering, preparing, and submitting the completed application form to the UPFTO. Then will vary depending upon the individual case. Any comments on the amount of time you require to complete this form andor suggestions for reducing this burden, should be sain to the file information. Officer, U.S. Patent and Trademark Office, P.D. Stot 1450, Abxxandid, VA 2231-31450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Sox 1450, Natural Andri, VA 2231-3450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 0851-0031

U.S. Platent and Trademark Office. U.S. DePartNets Or DeCoMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless Lootalins as valid CMB control number.

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of

Substitute for form 1449/PTO

Sheet

Application Number	10/599, 719
Filing Date	October 6, 2006
First Named Inventor	Lain-Yen Hii
Art Unit	
Examiner Name	
Altimery Doxiet Number	
PC 32225 A	

U. S. PATENT DOCUMENTS Publication Date Name of Patentee or ages, Columns, Lines, Where Examiner Document Number MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initiale\* No Number-Kind Code<sup>2</sup> (F known) Figures Appear US-HS. US-US-US. IIS-US-US-IIS-US-US-US-US-US-US-US-US. US-

Examiner Initials*	Cite No.1		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Te
initials.	NO.			Approant of Onco Boodiness		
		WO02060896A	08-08-2002	Pfizer Products Inc		
		WO03/065992A	08-14-2003	GTX Inc.		
			_			┝

		 _
Examiner	Date	
Signature	Considered	

"EXAMPLES initial if reference considered, whether or not citation is in conformance with MPEP 605 Daw line through citation if not in conformance and not considered, include copy of this form with most communication to applicate "Application" unique citation designation number (optionism number (optionism on a present and application). The citation of several code (WIPO Standard ST.3), "For Lagarence patient documents, the indication of the year of the reign of the Emperor must precede the seafer number of the patient documents are considered in the conformance of the patient documents are considered in the patient documents are considered in the patient document of th

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the multi-visible is to file (and by the USPTO to process) amapplication. Confidentially is governed by 38 U.S. C.122 and 37 CPR 1.14. This collection is estimated to level 2-burs to complete USPTO in confidentially is governed by 38 U.S. C.122 and 37 CPR 1.14. This collection is estimated to Event in complete in the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the embed of time by un require to complete this form andor suggestions for reducing this bursden, should be sent to the Chief Information Clorer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandrie, V.A. 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Dexandrie, V.A. 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

$\overline{}$		uction Ac	t of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid CMB control number.  Complete if Known		
Substitut	e for form 1449/PTO			Application Number	10/599,719	
INFO	ORMATION	DIS	CLOSURE	Filing Date	October 6, 2006	
STA	TEMENT E	Y A	PPLICANT	First Named Inventor	Lain-Yen Hu	
				Art Unit		
	(Use as many she	ets as ne	ecessary)	Examiner Name		
Sheet	3	of	-4	Attorney Docket Number	PC32225A	
_						

NON PATENT LITERATURE DOCUMENTS							
Examiner Cite Initials* No.1							
		Abstract: ARNOLD, DONALD R. et al., Radical ions in photochemistry. Part 20. The photochemical nucleophile-olefin combination, aromatic substitution reaction. Canadian Journal of Chemistry (1988) 66 (12), 2012-25.					
		GREGORIO ASENSIO ET AL., Synthesis of an enantiopure 2-aryley clobexanols form prochiral enol acetates by an enantinoselective protonation/diasteroselective reduction sequence, Tetrahedron: Asymmetry 14(2003) 3851-3855.					
		ALEXANDRE ALEXAKIS ET AL., Enantioselective Nucleophilic Opening fo meso Epoxides by Organolithium Reagents, SYNLETT October 1998, pages 1165-1167.					
		SHANKAR M. SHINGH ET AL., Androgen Receptor Antagonists (Antiandrogens): Structure-Activity Relationships, Current Medicinal Chemistry, 2000, 7, 211-247.					
		Derwent English Abstract of German Patent Application (DE3939116A1)					
		Micropatent English Abstract of Japanese Patent (JP2001-247411)					
		BOHL, CASEY E., ET AL, Structural basis for antagonism and resistance of bicalutamide in prostate cancer, PNAS, April 26, 2005, vol. 102, no. 17 pages 6201-6206.					
		PALUCKI, M. et al., "Palladium-eatalyzed intermolecular carbon-oxygen bond formation: A new systhesis of aryl ethers". J. Am. Chem. Soc., 1997, Vol. 119, nr. 14, pgs 3395-3396.					
		Co-pending commonly assigned United States patent application serial no. 11/053,010 filed February 8, 2005					
		DATABASE CA [Online] Chemical Abstracts Service, Columbus, Ohio, US. YASUDA, KOSUKE et al: "Preparation of aliphatic introgenous five-membered ring compounds as disperblyl peptidase IV inhibitors" XP002359473 retrived from STN Database accession no. 1563:25560					

1	Examiner		Date					
ı	Signature		Considered					
•	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not							

considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant is unique clation designation number (optional). 2 Applicant is unique clation designation is required by 37 CFR 1.8. The information is required by 37 CFR 1.8. The information is required by 38 LS. (2.12 and 37 CFR 1.1.4. This collection of information is required by 37 CFR 1.3. The information is required by 37 CFR 1.3. The information is required by 37 CFR 1.3. This solicitor is estimated to take 2 hours to complete, including pathering, preparing, and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any commands on the amount of time you require to complete this form and/or suggestions for reducing this busine, about the sent to the Child Information Chice, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandris, WA 2215-1450. DO NOT SERIOT ESS. OR COMPLETED FORMS TO THIS ADDRESS. SERIO TO:

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

_		uction Ac	t of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Substituti	for form 1449/PTO			Application Number	10/599,719	
INFO	RMATION	DIS	CLOSURE	Filing Date	October 6, 2006	
STA	TEMENT E	Y AI	PPLICANT	First Named Inventor	Lain-Yen Hu	
	(Use as many she			Art Unit		
	(Use as many sne	ets as ne	scessary)	Examiner Name		
Sheet	4	of	4	Attorney Docket Number	PC32225A	

Examiner Initials*	r Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), titl the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-is number(s), publisher, city and/or country where published.						
		DATABASI: CA [Online] Chemical Abstracts Service. Columbus, Ohio, US; CHAKL, HISAAKI ET AL: "Preparation and formulation of alkylsulfony biphenyl and ammiosulfonylbiphenyl derivatives as selective COX-2 mibribor's ZP002359472 retrieved from STD Database accession no L25300608					
		PATENT ABSTRACTS OF JAPAN vol. 013, no. 021 (C-560). 18 January 1989 (1989-61-18) & JP 63227502A (SDS BIOTECH KK), 21 September 1988 (1988-09-21)					
		REILING B A ET AL: "Effect of prenatal androgenization on performance, lactation, carcass, and sensory traits of heiters in a single-calf heiter system" JOURNAL OF ANIMAL SCIENCE, vol. 73, no. 4, 1995, pages 986-992, XPO					
		HETZMAN R.J.: "The effectiveness of anabolic agents in increasing rate of growth in funn animals, report on experiments in cattle." EINVIRONMENTAL QUIALITY AND SAPETY, SUPPLEMENT, 1976, no. 5, 1976, pages 89-98, XP008065222 ISSN: 0340-4714					
		BOTZKI, SALMEN: "Structure based design" COMINATORIAL SCIENCE, vol. 24, no. 4, 2005. pages 458-469, XP068065218					
		LOETTLER L.J. ET AL.: "Synthesis of Isosteres of P-Amidinophenylpyruvic Acid Inhibitors of Trypsin. Thrombin, and Pancratic Kalihkrein" I March 1975 J. Of Med Chem. Amer. Chem. Soc. Wash. Pages 287- 292 XP00675480 ISSN: 0022-2623					

CXAIIIIII		Duic	1
Signature		Considered	
*EXAMINER: Ir	itial if reference considered, whether or not citation is in conformance with MPEP 60:	<ol><li>Draw line through c</li></ol>	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique claimto designation number (optional). 2 Applicant's unique claimto designation can under to glorally. 2 Applicant's unique claimto designation can under to glorally. 2 Applicant's unique claimto designation confideration is required by 3T CFR 1.18. This information is required by 3T CFR 1.18. This collection is entired to take 2 hours to complete, recluding pathering, preparing, and submitting the completed application form to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this buttern, about do sent to the Chall Information Officer, U.S. Petent and Tredemark Office, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: COmmissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450.